Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
104 hedge funds and large institutions have $55.7M invested in Orexigen Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 33 increasing their positions, 34 reducing their positions, and 25 closing their positions.
3% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 34
14% less funds holding
Funds holding: 121 → 104 (-17)
56% less call options, than puts
Call options by funds: $162K | Put options by funds: $366K
66% less capital invested
Capital invested by funds: $164M → $55.7M (-$109M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
68% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$26M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.02M |
| 3 |
Morgan Stanley
New York
|
+$1.02M |
| 4 |
DY
Dowling & Yahnke
San Diego,
California
|
+$888K |
| 5 |
Renaissance Technologies
New York
|
+$799K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.44M |
| 3 |
Millennium Management
New York
|
-$4.46M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.36M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.16M |
OREX Hedge Fund Activity: Q1 2016 in Review
104 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q1 2016, worth a combined $55.7M — down 66% from $164M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of OREX and 8 opened new positions — a net loss of 17 holders — while 34 trimmed existing stakes and 33 added.
The largest buyer was Baupost Group, adding an estimated $26M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $11.2M sold.
- 104 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q1 2016, down from 121 in Q4 2015.
- Funds reported $55.7M of Orexigen Therapeutics, Inc. stock for Q1 2016, down 66% quarter-over-quarter.
- 8 funds opened new Orexigen Therapeutics, Inc. positions in Q1 2016 and 25 closed out, a net change of -17 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q1 2016 was Baupost Group, an estimated $26M added.
- The largest Orexigen Therapeutics, Inc. seller in Q1 2016 was T. Rowe Price Associates, an estimated $11.2M sold.
Based on aggregated 13F filings for Q1 2016.